Prashant Kapoor, MD, on New Data on Combination Regimen From Phase III Trial in Multiple Myeloma

Posted: Monday, February 5, 2024

Prashant Kapoor, MD, of the Mayo Clinic, Minnesota, presents the findings from the phase III IsKia trial, also known as the EMN24 study, which investigated the combination of isatuximab, carfilzomib, lenalidomide, and dexamethasone as a pretransplant induction regimen for patients with newly diagnosed multiple myeloma. These findings were presented by Dr. Francesca Gay at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.

---